Aura reports positive Phase 2 bel-sar results: 80% tumor control, 90% vision preservation

Aura Biosciences, Inc.

Bel-sar achieved 80% tumor control rate in Phase 3-eligible patients (8/10); complete cessation of growth post-treatment.
Visual acuity preserved in 90% of 10 patients; 80% had high-risk tumors near fovea/optic disc.
No treatment-related serious adverse events; mild Grade 1 ocular AEs self-limited, resolved in median 6 days.
FDA agreed under Special Protocol Assessment for Phase 3 CoMpass trial; enrollment ongoing.
Virtual investor event today at 8:00 am ET featuring key opinion leaders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.